APA (7th ed.) Citation

KL, C., L, G., S, S., X, S., L, F., MR, B., . . . SK, T. (2025). Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. Blood cancer journal, 15(1), 211. https://doi.org/10.1038/s41408-025-01415-5

Chicago Style (17th ed.) Citation

KL, Chohan, et al. "Long-term Outcomes and Treatment Patterns in Waldenström Macroglobulinemia Patients Who Discontinue Bruton Tyrosine Kinase Inhibitor (BTKi) Therapy." Blood Cancer Journal 15, no. 1 (2025): 211. https://doi.org/10.1038/s41408-025-01415-5.

MLA (9th ed.) Citation

KL, Chohan, et al. "Long-term Outcomes and Treatment Patterns in Waldenström Macroglobulinemia Patients Who Discontinue Bruton Tyrosine Kinase Inhibitor (BTKi) Therapy." Blood Cancer Journal, vol. 15, no. 1, 2025, p. 211, https://doi.org/10.1038/s41408-025-01415-5.